A nationwide 12‐month observatory of automated insulin delivery shows improved glucose control, sustained adoption, and reduced acute severe events
Authors' conclusion
Twelve months of AID use in routine care improved glucose control in PwT1D, among whom there was less experienced SH and a minor discontinuation.
Study context
- Population
- Adults and children with T1D initiating AID in routine care, 79 centres; 44.4% male, median age 38 years, BMI 24.5 kg/m², diabetes duration 19 years; MiniMed 780G 49.7%, Tandem Control-IQ 49.3%
- Participants
- 2,741 adults
- Exposure
- Before vs after 12 months of AID
- AIDn = 2,741
- Outcome
- Change in TIR (3.9-10 mmol/L)
- Follow-up
- 1 year
Methodological detailsmulticentre, 79 centres
- Multicentre
- 79 centres
Main finding
As reported in the abstract
TIR (3.9-10 mmol/L), baseline to 12 months
- Time in range (TIR) increased from 58.0 [IQR 21] to 70.1% [IQR 14]; p < 0.05
- Median [IQR]
Observational data: associations, not effects.
Further findings
HbA1c, baseline to 12 months
- HbA1c decreased from 7.6 [IQR 1.2] to 7.0% [IQR 0.8]; p < 0.05
- Median [IQR]
Time course of improvements · 3 to 12 months
- All improvements observed after 3 months and sustained through 12 months
AID discontinuation
- Discontinued AID
- 2.8%
Safety
Acute severe events, baseline to 12 months
- PwT1D with severe hypoglycaemia decreased from 4.1 to 0.9%; p < 0.05
- PwT1D with ketoacidosis decreased from 1.2 to 0.6%; p < 0.05
Original publication
A nationwide 12‐month observatory of automated insulin delivery shows improved glucose control, sustained adoption, and reduced acute severe events. Diabetes Obes Metab. Published 24 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →